Pulsara and iSchemaView Launch Rapid Integration for Stroke Care Team Collaboration


February 5, 2019—Pulsara announced that it has partnered with iSchemaView to allow Pulsara's open application programming interface (API) infrastructure to streamline the sharing of iSchemaView's Rapid imaging platform for stroke care collaboration.

According to the company, Pulsara's mobile platform was developed to improve coordination and communication tasks for rapid assessment and care of patients with time-sensitive conditions, such as stroke. The stroke workflow within the platform enables clinicians to share images, stroke scores, contraindications for tissue plasminogen activator, and other specialized care information to enable efficient and timely communication for stroke teams. Pulsara's real-time communication network allows clinicians communicate using audio, video, instant messaging, data, images, and key benchmarks.

The integration of the Pulsara API and iSchemaView Rapid platform enables coordinated real-time sharing of the Rapid neuroimaging platform's images (including CT perfusion, MRI, and CTA) with the entire stroke team.

In January, iSchemaView announced FDA clearance of the Rapid platform for use in selecting stroke patients who are likely to benefit from endovascular thrombectomy. The Rapid platform automatically provides CT and MRI brain images indicating perfusion and angiographic blood flow abnormalities that identify severely damaged tissue versus tissue at risk, stated the company.


Contact Info

For advertising rates and opportunities, contact:
Craig McChesney

Stephen Hoerst

Charles Philip

About Endovascular Today

Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurologists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.